Your email has been successfully added to our mailing list.

×
-0.00476803148414421 -0.00476803148414421 -0.00476803148414421 -0.00476803148414421 -0.0161204873987738 -0.0161204873987738 -0.0161204873987738 -0.0161204873987738
Stock impact report

Kamada Announces Additional Interim Results from Phase 2 Proof of Concept Clinical Trial of Intravenous Alpha-1 Antitrypsin Treatment for Prevention of Lung Transplant Rejection

Kamada Ltd. - Ordinary Shares (KMDA) 
Last kamada ltd. - ordinary shares earnings: 2/12 07:00 am Check Earnings Report
US:NASDAQ Investor Relations: kamada.com/investors.php
Company Research Source: GlobeNewswire
Kamada’s IV-AAT demonstrated a trend towards improvements in multiple clinical outcomes, including days on mechanical ventilation post-transplant, pulmonary function at week 4 and week 48 post-transplant and six-minute walk test. Top-line Results Anticipated in H2 2019 REHOVOT, Israel, Feb. 06, 2019 (GLOBE NEWSWIRE) -- Kamada Ltd. (NASDAQ & TASE: KMDA), a plasma-derived protein therapeutics company focused on orphan indications, today announced interim results from the Company’s Phase 2 trial of intravenous Alpha-1 Antitrypsin (IV-AAT) for the prevention of lung transplant rejection following one year of treatment for all patients. The study is being conducted at the Rabin Medical Center - Beilinson Hospital in Israel, under the leadership of Professor Mordechai R. Kramer, M.D., Director of the Institute of Pulmonary Medicine at the Center.  The study is being conducted in collaboration with Shire plc, now owned by Takeda. The Phase 2 proof-of-concept trial is a randomized, open- Show less Read more
Impact Snapshot
Event Time:
KMDA
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison Updated
Event Day
Stock performance from the time of news release until the following 4pm ET market close
Last price at news event
Since Event
Multi-day stock performance from the time of the news release
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
LAST
PRICE AT
NEWS EVENT
SINCE EVENT
Multi-day stock performance from the time of the news release
Last Price
VWAP
High:
Max Up
High:
Low:
Max Down
Low:
%
Post news range
%
Price change

Price Change Percentage


S&P 500
(SPX)

%

Volume ratio
%

Volume
Ticks

Avg transaction size

Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Opt-in for
KMDA alerts

from News Quantified
Opt-in for
KMDA alerts

from News Quantified